Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice
Journal of Virology · 2024
DOI: 10.1128/jvi.00521-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Junda Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China. Hauptthemen laut MEDLINE: Vaccinia virus, Antibodies, Viral, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), MOST | National Key Research and Development Program of China (NKPs), | Beijing Nova Program.
Abstract (Originalsprache)
The reoccurrence of successive waves of SARS-CoV-2 variants suggests the exploration of more vaccine alternatives is imperative. Modified vaccinia virus Ankara (MVA) is a virus vector exhibiting excellent safety as well as efficacy for vaccine development. Here, a series of recombinant MVAs (rMVAs) expressing monomerized or trimerized S proteins from different SARS-CoV-2 variants are engineered. Trimerized S expressed from rMVAs is found predominantly as trimers on the surface of infected cells. Remarkably, immunization of mice with rMVAs demonstrates that S expressed in trimer elicits higher levels of binding IgG and IgA, as well as neutralizing antibodies for matched and mismatched S proteins than S in the monomer. In addition, trimerized S expressed by rMVA induces enhanced cytotoxic T-cell responses than S in the monomer. Importantly, the rMVA vaccines expressing trimerized S exhibit superior protection against a lethal SARS-CoV-2 challenge as the immunized animals all survive without displaying any pathological conditions. This study suggests that opting for trimerized S may represent a more effective approach and highlights that the MVA platform serves as an ideal foundation to continuously advance SARS-CoV-2 vaccine development. IMPORTANCE MVA is a promising vaccine vector and has been approved as a vaccine for smallpox and mpox. Our analyses suggested that recombinant MVA expressing S in trimer (rMVA-ST) elicited robust cellular and humoral immunity and was more effective than MVA-S-monomer. Importantly, the rMVA-ST vaccine was able to stimulate decent cross-reactive neutralization against pseudoviruses packaged using S from different sublineages, including Wuhan, Delta, and Omicron. Remarkably, mice immunized with rMVA-ST were completely protected from a lethal challenge of SARS-CoV-2 without displaying any pathological conditions. Our results demonstrated that an MVA vectored vaccine expressing trimerized S is a promising vaccine candidate for SARS-CoV-2 and the strategy might be adapted for future vaccine development for coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
- State Key Laboratory of Pathogen and Biosecurity, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, China.
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- MOST | National Key Research and Development Program of China (NKPs)
- | Beijing Nova Program
- 北京市科学技术委员会 | Beijing Nova Program
Zitieren
APA
Zhu, J., Wang, Z., Li, Y., Zhang, Z., Ren, S., Wang, J., Xie, S., Liao, Z., Song, B., Wu, W., Yan, F., & Peng, C. (2024). Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice. Journal of Virology. https://doi.org/10.1128/jvi.00521-24
Vancouver
Zhu J, Wang Z, Li Y, Zhang Z, Ren S, Wang J, et al. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice. Journal of Virology. 2024. doi:10.1128/jvi.00521-24
BibTeX
@article{Zhu2024,
author = {Zhu, Junda and Wang, Zhenshan and Li, Yarui and Zhang, Zihui and Ren, Shuning and Wang, Jing and Xie, Shijie and Liao, Zhiyi and Song, Baifen and Wu, Wenxue and Yan, Feihu and Peng, Chen},
title = {Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.00521-24}
}
EUVIMED